Freitag, 15. Januar 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 

JOURNAL ONKOLOGIE – STUDIE

Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer

Rekrutierend

NCT-Nummer:
NCT03560102

Studienbeginn:
Januar 2020

Letztes Update:
19.02.2020

Wirkstoff:
-

Indikation (Clinical Trials):
Breast Neoplasms, Carcinoma, Ductal, Breast

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Kantonsspital Winterthur KSW

Collaborator:
-

Studienleiter

Christoph A Binkert, MD
Principal Investigator
Kantonsspital Winterthur KSW

Kontakt

Studienlocations (1 von 1)

Kantonsspital Winterthur
CH-8401 Winterthur
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Christoph A Binkert, MD
Phone: +41 52 266 26 02
E-Mail: christoph.binkert@ksw.ch

Marlene Wegmann Oswald, PhD
Phone: +41 52 266 23 29
E-Mail: marlene.wegmann@ksw.ch
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

The dedicated MR-HIFU unit has been shown to be safe and feasible to ablate breast tissue.

The planned study should address the possibility to completely ablate breast cancer with the dedicated breast MR-HIFU unit. The result of the MR-HIFU therapy should be monitored by imaging (contrast enhanced MRI) as well as with histopathological correlation after surgery.

The patient population would consist of female patients with proven breast cancer scheduled for surgical lumpectomy or mastectomy.

The idea is to evaluate a minimal invasive method to treat breast cancer as a potential alternative to surgical resection in the future

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Informed Consent as documented by signature

- World Health Organization (WHO) performance status≤ 2

- Body weight ≤ 80 kg

- Biopsy proven invasive breast cancer with a size of ≤3.0cm (TNM classification: cT1-2 N0-2 MX ).

- Histological type of tumor: invasive ductal carcinoma (IDC)

- Patient is scheduled for surgical resection of tumor at study site

- Tumor location within the reach of the HIFU transducers with the patient in prone position; distance from skin and pectoral muscle to the tumor ≥ 1.0 cm.

- Target breast fits in the cup of the dedicated MR-HIFU breast system

Exclusion Criteria:

- neoadjuvant systemic therapy

- prior radiotherapy in target breast

- contraindications for MRI

- contraindication for application of gadolinium-based contrast agent

- contraindication for procedural sedation analgesia

- macro-calcifications in or around the targeted tumor

- scar tissue or surgical clips in the direct path of the ultrasound beams

- Women who are pregnant or breast feeding,

- Intention to become pregnant during the course of the study,

- Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.

- Known or suspected non-compliance, drug or alcohol abuse,

- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,

- Participation in another study with investigational drug/device within the 30 days preceding and during the present study,

- Previous enrolment into the current study

Studien-Rationale

Primary outcome:

1. Accuracy of MRI as method for assessment of quantitative treatment success (correlation with results of the histopathological analysis performed as reference method) (Time Frame - Day 14):
Quantitative assessment: Correlation between MRI and histopathology results (volume of necrosis)

2. Accuracy of MRI as method for assessment of qualitative treatment success (correlation with results of the histopathological analysis performed as reference method) (Time Frame - Day 14):
Qualitative assessment: spatial congruence of ablated tumor tissue and width of margin

Secondary outcome:

1. Assessment of treatment efficacy (Time Frame - Day 14):
Effective treatment is defined as complete necrosis (100%) of targeted tumor including safety margin (>1mm) (histopathological analysis). Safety margin: measurement of smallest margin on histology and measurement of smallest margin on MRI. Parameter: Percentage of necrosis including safety margin

Geprüfte Regime

  • Philips Sonalleve® MR-HIFU Breast Therapy System:
    The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.

Quelle: ClinicalTrials.gov


ASH 2020
  • Phase-III-Studie ASCEMBL bei resistenten/intoleranten Patienten mit CML: STAMP-Inhibitor Asciminib deutlich effektiver als TKI Bosutinib
  • Ruxolitinib-resistente/-intolerante MF-Patienten profitieren im klinischen Alltag möglicherweise von einer Rechallenge
  • Real-world-Daten zu PV: Rechtzeitige Umstellung von HU auf Ruxolitinib wirkt möglicherweise Anstieg thromboembolischer Ereignisse entgegen
  • 5-Jahres-Daten der RESPONSE-2-Studie: Überlegenheit von Ruxolitinib gegenüber BAT im Langzeitverlauf bestätigt
  • Phase-I-Studie: Anhaltendes molekulares Ansprechen mit neuem BCR-ABL-Inhibitor Asciminib bei CML-Patienten mit T315I-Resistenzmutation
  • Patienten mit ITP sind emotional erheblich belastet
  • r/r DLBCL: Vielversprechende erste Daten zur CAR-T-Zell-Therapie mit Tisagenlecleucel in Kombination mit Ibrutinib
  • r/r FL: CAR-T-Zell-Therapie mit Tisagenlecleucel wirksam und sicher
  • Myelofibrose: Ruxolitinib-Startdosis von 10 mg 2x tägl. auch bei initial niedriger Thrombozytenzahl sicher anwendbar
  • Phase-III-Studie REACH3: Ruxolitinib bei chronischer steroidrefraktärer oder steroidabhängiger GvHD wirksamer als die beste verfügbare Therapie